ProCE Banner Activity

Expert Guidance for Treatment Decisions in Advanced Prostate Cancer

Tool

Use this Interactive Decision Support Tool to compare your choice of therapy for patients with prostate cancer with 5 expert recommendations. 

Released: September 26, 2023

Share

Faculty

Tanya B. Dorff

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California

Alicia Morgans

Alicia Morgans, MD, MPH

Associate ProfessorDana-Farber Cancer InstituteBoston, Massachusetts

Michael Schweizer

Michael Schweizer, MD

Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

David VanderWeele

David VanderWeele, MD, PhD

Associate Professor
Department of Hematology/Oncology
Northwestern University
Attending Physician
Department of Hematology/Oncology
Jesse Brown VA Medical Center
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC., in partnership with ZERO Prostate Cancer.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lilly

Novartis

Partners

ZERO Prostate Cancer

ProCE Banner

Faculty Disclosure

Primary Author

Tanya B. Dorff, MD

Professor of Medicine
Vice Chair for Clinical Affairs
Department of Medical Oncology
City of Hope National Medical Center
Duarte, California

Tanya B. Dorff, MD: consultant/advisor/speaker: AstraZeneca, Bayer, Sanofi.

Rana R. McKay, MD

Associate Professor of Medical Oncology and Urology
Associate Director, Clinical Sciences
Co-Lead, Genitourinary Malignancies Program
Moores Cancer Center
University of California San Diego
La Jolla, California

Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bristol-Myers Squibb, Bayer, Calithera, Caris, Dendreon, Eisaix, Exelixis, Johnson & Johnson, Lilly, Myovant, Merck, Novartis, Pfizer, Sanofi, Seagen, Sorrento, Telix, Tempus; research funding (paid to institution): Artera, Bayer, BMS, Exelixis, AstraZeneca, Oncternal, Tempus. 

Alicia Morgans, MD, MPH

Associate ProfessorDana-Farber Cancer InstituteBoston, Massachusetts

Alicia K. Morgans, MD, MPH: consultant/advisor/speaker: AAA, Astellas, AstraZeneca, Bayer, Dendreon, Foundation Medicine, Exelixis, Janssen, Lantheus, Myovant, Myriad, Novartis, Pfizer, Sanofi, SeaGen, Telix.

Michael Schweizer, MD

Associate Professor
Clinical Research Division
Department of Medical Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

Michael T. Schweizer, MD: consultant/advisor/speaker: AstraZeneca, PharmaIn, Sanofi; researcher (paid to institution): Ambrx, AstraZeneca, Bristol Myers Squibb, Epigenetics, Epigenetix, Hoffman-La Roche, Immunomedics, Incyte, Janssen, Merck, Novartis, Pfizer, SignalOne Bio, Tmunity, Xencoer, Zenith.

David VanderWeele, MD, PhD

Associate Professor
Department of Hematology/Oncology
Northwestern University
Attending Physician
Department of Hematology/Oncology
Jesse Brown VA Medical Center
Chicago, Illinois

David VanderWeele, MD, PhD: consultant/advisor/speaker: Astellas, AstraZeneca Bayer, Exelixis, Janssen, Myovant; researcher (paid to institution): AstraZeneca, Bayer, Genentech.